Pharmaceuticals, Biotechnology and Life Sciences
The Milken Institute COVID-19 Treatment and Vaccine Tracker has identified more than 111 vaccines and 197 treatments in the pipeline to treat and prevent COVID-19.
During the COVID-19 crisis, it is critical for companies in the pharmaceutical market to take calculative and well-executed measures to ensure business continuity in the long run.
Arcturus Therapeutics and Catalent have entered a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus.
Gilead get’s authorization of emergency use of Remdesivir to treat hospitalized patients with severe COVID-19 disease in the United States.
Moderna has engaged with Lonza to work on its novel coronavirus vaccine, with a goal to enable manufacturing of up to 1 billion doses per year, noting that technology transfer is expected to begin in June 2020.
Shionogis’ Fetcroja (cefiderocol) in the end of April 2020 received European Commission (EC) marketing authorisation for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options.
University Hospitals Cleveland Medical Center, a nationally ranked hospital, is ready to start screening patients CLEVELAND–(BUSINESS WIRE)–$ATHX #ARDS–Athersys, Inc. (NASDAQ:…
Nicoya, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, announced today that they will be offering Surface Plasmon Resonance (SPR) technical support to all researchers – at no cost – during COVID-19.
JCRI said Wednesday it is seeking approval from the Food and Drug Administration (FDA) under its Emergency Use Authorization (EUA) for using the Canady Helios Cold Plasma HERO (Humidified Electrical Reactive Oxygen) System for the treatment of patients infected with COVID-19 virus.
Sales rep training, forecasting, competitive intelligence, patient support services, and KOL relationship management are among the functions within the pharmaceutical commercial model most in need of change during and post-pandemic.